Author’s response to reviews

Title: Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis

Authors:

Myrlene Aigbogun (Mylene.Sanon@otsuka-us.com)
Robert Stellhorn (Robert.Stellhorn-CW@otsuka.com)
Ann Hartry (AHRY@lundbeck.com)
Ross Baker (Ross.Baker@otsuka-us.com)
Howard Fillit (fillitconsulting@gmail.com)

Version: 4 Date: 12 Feb 2019

Author’s response to reviews:

Senior Assistant Editor
BMC Neurology

Dear Sir or Madam,

On behalf of my fellow authors, thank you for providing additional comments for our revised version of our manuscript "Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis" (Manuscript ID#: NURL-D-18-00107) for publication in BMC Neurology.

We hope that you will find our revised manuscript suitable for publication in BMC Neurology. If you have additional comments, please do not hesitate to contact me.

Sincerely,

Myrlene Sanon Aigbogun

Otsuka America Pharmaceutical
508 Carnegie Center, Princeton, NJ 08540
Tel: (609) 512-4456
myrlene.sanon@otsuka-us.com
Responses to Senior Assistant Editor

1. Please move lines 392-394 to the 'Ethics Approval and Consent to Participate' section.

Response: Lines 392 to 394 have been moved to the ‘Ethics Approval and Consent to Participate’ section.

2. Please include the full name of the institutional review board (and the institute to which it belongs to) that declared the study exempt from needing ethics approval and the committee’s reference number if appropriate.

Response: The following has been added under ‘Ethics Approval and Consent to Participate’:

The data used for this study did not involve the interaction or interview with any subjects and the data does not include any individually identifiable data (e.g. does not include names, addresses, social security or medical record numbers or other obvious identifiers) and as such is not research involving human subject as defined at 45 CFR 46.102(f)(2). Furthermore, this study used existing fully de-identified and the investigator(s) cannot be identified, directly or through identifiers linked to subjects and as such is exempt from 45 CFR 46.101(b)(4) from all 45 CFR part 46 requirements. Consequently IRB approval is not required.